Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

Biochemical Pharmacology

Volumn 78, Issue 5, 2009, Pages 460-468

  La Monica, Silvia ^a   Galetti, Maricla ^a   Alfieri, Roberta R ^a   Cavazzoni, Andrea ^a   Ardizzoni, Andrea ^b   Tiseo, Marcello ^b   Capelletti, Marzia ^b   Goldoni, Matteo ^b   Tagliaferri, Sara ^b   Mutti, Antonio ^b   Fumarola, Claudia ^a   Bonelli, Mara ^a   Generali, Daniele ^c   Petronini, Pier Giorgio ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c Centro di Medicina Molecolare   (Italy)

Author keywords

EGFR; Everolimus; Gefitinib; Lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; GEFITINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; S6 KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DEATH; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG NEOPLASMS; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 67649781695     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.04.033     Document Type: Article

References (51)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Carney D.N. Lung cancer-time to move on from chemotherapy. N Engl J Med 346 (2002) 126-128
3. Bunn Jr. P.A. Current therapeutic approaches in lung cancer. Clin Lung Cancer 4 Suppl. 1 (2002) S4
4. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 23 (2005) 3235-3242
5. Ciardiello F., and Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 358 (2008) 1160-1174
6. Sharma S.V., Bell D.W., Settleman J., and Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7 (2007) 169-181
7. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 (2005) e73
8. Camp E.R., Summy J., Bauer T.W., Liu W., Gallick G.E., and Ellis L.M. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11 (2005) 397-405
9. Engelman J.A., and Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 18 (2008) 73-79
10. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., and Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284 (2003) 31-53
11. Engelman J.A., Janne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 102 (2005) 3788-3793
12. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8 (2005) 179-183
13. Morgillo F., and Lee H.Y. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Update 8 (2005) 298-310
14. Marinov M., Fischer B., and Arcaro A. Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol 63 (2007) 172-182
15. Balsara B.R., Pei J., Mitsuuchi Y., Page R., Klein-Szanto A., Wang H., et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25 (2004) 2053-2059
16. Johnson B.E., Jackman D., and Janne P.A. Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Clin Cancer Res 13 (2007) s4628-s4631
17. Papadimitrakopoulou V., Soria J.C., Douillard J.Y., Giaccone G., Wolf J., Crino L., et al. A phase II study of RAD001 (R) (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I). J Clin Oncol 25 18 Suppl. (2007) 406s
18. Gridelli C., Maione P., and Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 13 (2008) 139-147
19. Milton D.T., Riely G.J., Azzoli C.G., Gomez J.E., Heelan R.T., Kris M.G., et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 110 (2007) 599-605
20. Riely G.J., Kris M.G., Zhao B., Akhurst T., Milton D.T., Moore E., et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13 (2007) 5150-5155
21. Carmi C., Cavazzoni A., Zuliani V., Lodola A., Bordi F., Plazzi P.V., et al. 5-benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity. Bioorg Med Chem Lett 16 (2006) 4021-4025
22. Cavazzoni A., Petronini P.G., Galetti M., Roz L., Andriani F., Carbognani P., et al. Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line. Oncogene 23 (2004) 8439-8446
23. Gillies R.J., Didier N., and Denton M. Determination of cell number in monolayer cultures. Anal Biochem 159 (1986) 109-113
24. Cavazzoni A., Alfieri R.R., Carmi C., Zuliani V., Galetti M., Fumarola C., et al. Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. Mol Cancer Ther 7 (2008) 361-370
25. Goldoni M., Vettori M.V., Alinovi R., Caglieri A., Ceccatelli S., and Mutti A. Models of neurotoxicity: extrapolation of benchmark doses in vitro. Risk Anal 23 (2003) 505-514
26. Goldoni M., and Johansson C. A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. Toxicol In Vitro 21 (2007) 759-769
27. Tiseo M., Capelletti M., De Palma G., Franciosi V., Cavazzoni A., Mozzoni P., et al. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. J Thorac Oncol 3 (2008) 1104-1111
28. Van Schaeybroeck S., Kyula J., Kelly D.M., Karaiskou-McCaul A., Stokesberry S.A., Van Cutsem E., et al. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther 5 (2006) 1154-1165
29. Deng J., Shimamura T., Perera S., Carlson N.E., Cai D., Shapiro G.I., et al. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 67 (2007) 11867-11875
30. Guo A., Villen J., Kornhauser J., Lee K.A., Stokes M.P., Rikova K., et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 105 (2008) 692-697
31. Janmaat M.L., Rodriguez J.A., Gallegos-Ruiz M., Kruyt F.A., and Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 118 (2006) 209-214
32. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., et al. The T790 M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105 (2008) 2070-2075
33. Parra H.S., Cavina R., Latteri F., Zucali P.A., Campagnoli E., Morenghi E., et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 91 (2004) 208-212
34. Ono M., Hirata A., Kometani T., Miyagawa M., Ueda S., Kinoshita H., et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 3 (2004) 465-472
35. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
36. Sordella R., Bell D.W., Haber D.A., and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004) 1163-1167
37. Boulay A., Zumstein-Mecker S., Stephan C., Beuvink I., Zilbermann F., Haller R., et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64 (2004) 252-261
38. Boffa D.J., Luan F., Thomas D., Yang H., Sharma V.K., Lagman M., et al. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 10 (2004) 293-300
39. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65 (2005) 7052-7058
40. Mabuchi S., Altomare D.A., Cheung M., Zhang L., Poulikakos P.I., Hensley H.H., et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 13 (2007) 4261-4270
41. Noh W.C., Mondesire W.H., Peng J., Jian W., Zhang H., Dong J., et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10 (2004) 1013-1023
42. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66 (2006) 1500-1508
43. Buck E., Eyzaguirre A., Brown E., Petti F., McCormack S., Haley J.D., et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5 (2006) 2676-2684
44. Bianco R., Garofalo S., Rosa R., Damiano V., Gelardi T., Daniele G., et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 98 (2008) 923-930
45. Azzariti A., Porcelli L., Gatti G., Nicolin A., and Paradiso A. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem Pharmacol 75 (2008) 1035-1044
46. Jimeno A., Kulesza P., Wheelhouse J., Chan A., Zhang X., Kincaid E., et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 96 (2007) 952-959
47. Johansson G., Mahller Y.Y., Collins M.H., Kim M.O., Nobukuni T., Perentesis J., et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther 7 (2008) 1237-1245
48. Kris M.G., Riely G.J., Azzoli C.G., Heelan R.T., Krug L.M., Pao W., et al. Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: a phase II trial. J Clin Oncol 25 18 Suppl. (2007) 403 s
49. Martin B., Paesmans M., Mascaux C., Berghmans T., Lothaire P., Meert A.P., et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 91 (2004) 2018-2025
50. Vesselle H., Salskov A., Turcotte E., Wiens L., Schmidt R., Jordan C.D., et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol 3 (2008) 971-978
51. Sunaga N., Oriuchi N., Kaira K., Yanagitani N., Tomizawa Y., Hisada T., et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 59 (2008) 203-210